Betaine for diabetes: preclinical promise, conflicting human evidence, gut Microbiota-TMAO confounder, and pathways toward rigorous clinical translation

Betaine (N,N,N-trimethylglycine), abundant in sugar beets, spinach and quinoa, acts as mammalian cellular osmoprotectant and core one-carbon methyl donor. This translational review synthesizes epidemiological, preclinical and clinical evidence on betaine-diabetes interactions, with strict stratification of evidence tiers including cell assays, rodent models, human observational cohorts and randomized controlled trials (RCTs). Observational data show inverse correlations between circulating betaine and incident type 2 diabetes (T2D), whereas meta-analyses find no consistent protective effect of dietary betaine intake, confounded by lifestyle bias and diabetes-related renal reverse causation. In vitro and rodent models confirm betaine alleviates insulin resistance through coordinated IRS1-AKT, AMPK, anti-oxidative and endoplasmic reticulum stress pathways, plus upregulated FGF21 and enhanced mitochondrial function. Preclinical rodent data demonstrate betaine’s protective effects against diabetic micro- and macrovascular complications (nephropathy, retinopathy, neuropathy, cardiovascular damage), yet no human RCTs validate these organ benefits. Gut microbes convert betaine to TMAO, a metabolite associated with higher cardiometabolic and T2D risk, leading to variable individual responses to oral supplementation. The single small, short prediabetes randomized controlled trial available to date yielded no robust glycemic benefits but raised plasma TMAO, precluding the routine clinical use of supplemental betaine for management of T2D or gestational diabetes mellitus (GDM). Future work demands large long-term stratified human trials, microbiota-targeted co-interventions and novel betaine derivatives to separate therapeutic effects from microbial trimethylamine generation.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-20
DOI
https://doi.org/10.3389/fphar.2026.2011683
Primary Topic
Aldose Reductase and Taurine
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Betaine for diabetes: preclinical promise, conflicting human evidence, gut Microbiota-TMAO confounder, and pathways toward rigorous clinical translation

Tingting Jiang, K Xie, Dacheng Xie
2 links
Frontiers in Pharmacology
Aldose Reductase and Taurine
article

Betaine for diabetes: preclinical promise, conflicting human evidence, gut Microbiota-TMAO confounder, and pathways toward rigorous clinical translation

Tingting Jiang, K Xie, Dacheng Xie
article en

Abstract

Betaine (N,N,N-trimethylglycine), abundant in sugar beets, spinach and quinoa, acts as mammalian cellular osmoprotectant and core one-carbon methyl donor. This translational review synthesizes epidemiological, preclinical and clinical evidence on betaine-diabetes interactions, with strict stratification of evidence tiers including cell assays, rodent models, human observational cohorts and randomized controlled trials (RCTs). Observational data show inverse correlations between circulating betaine and incident type 2 diabetes (T2D), whereas meta-analyses find no consistent protective effect of dietary betaine intake, confounded by lifestyle bias and diabetes-related renal reverse causation. In vitro and rodent models confirm betaine alleviates insulin resistance through coordinated IRS1-AKT, AMPK, anti-oxidative and endoplasmic reticulum stress pathways, plus upregulated FGF21 and enhanced mitochondrial function. Preclinical rodent data demonstrate betaine’s protective effects against diabetic micro- and macrovascular complications (nephropathy, retinopathy, neuropathy, cardiovascular damage), yet no human RCTs validate these organ benefits. Gut microbes convert betaine to TMAO, a metabolite associated with higher cardiometabolic and T2D risk, leading to variable individual responses to oral supplementation. The single small, short prediabetes randomized controlled trial available to date yielded no robust glycemic benefits but raised plasma TMAO, precluding the routine clinical use of supplemental betaine for management of T2D or gestational diabetes mellitus (GDM). Future work demands large long-term stratified human trials, microbiota-targeted co-interventions and novel betaine derivatives to separate therapeutic effects from microbial trimethylamine generation.

Frontiers in PharmacologyVol. 17
Tongji University (CN), Shanghai Pulmonary Hospital (CN), South China University of Technology (CN), Air Force Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province
Good health and well-being
Aldose Reductase and Taurine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon